Peanut Allergy clinical trials at UCSD
1 research study open to eligible people
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
open to eligible people ages 1-3
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
San Diego, California and other locations
Last updated: